?> Contact us Follow Us
Biosimilars Forum
  • About Us
    • Members
    • Executive Director
  • Why Biosimilars
    • The Issue
    • Our Solutions
  • Biosimilars 101
    • Foundations
    • Core Principles
    • FDA Regulatory Tenets
    • Biosimilars FAQs
    • Future Evolution of Biosimilar Development
    • Approved Biosimilars
  • Advocacy
    • Our Action
    • Tools
  • News
  • Resources
  • Get Involved
    • Partners

News

Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
November 2, 2023 signalgroup
Biosimilars Forum Announces Support for Bipartisan Interchangeability Legislation
News
October 17, 2023 signalgroup
Biosimilars Forum Welcomes Meitheal Pharmaceuticals as Newest Member
News
October 10, 2023 signalgroup
Biosimilars Forum Welcomes Amneal as Newest Member
News
August 30, 2023 signalgroup
Biosimilars Forum Statement on CMS Announcement of Drug Negotiation List 
News
August 7, 2023 signalgroup
Biosimilars Forum Scientific Publication Identifies Pathway to Streamlined Development for Biosimilars
News
July 25, 2023 signalgroup
Biosimilars Forum Applauds Boehringer Ingelheim for Launch of Cyltezo®
News
July 10, 2023 signalgroup
Biosimilars Forum Congratulates Fresenius Kabi for Launch of IDACIO®
News
July 6, 2023 signalgroup
Biosimilars Forum Applauds Sandoz for Launch of Hyrimoz®
News
July 6, 2023 signalgroup
Biosimilars Forum Applauds Organon and Samsung Bioepis for Launch of HADLIMA™
News
July 5, 2023 signalgroup
Biosimilars Forum Applauds Coherus for Launch of YUSIMRY™
  • Prev page
  • 01
  • 02
  • 03
  • 04
  • 05
  • Next page

  • Biosimilars 101
  • Biosimilars FAQs
  • Advocacy
  • Stay Connected
Biosimilars Forum
© 2025 Biosimilars Forum. All rights reserved.
  • Terms of Use
  • |
  • Privacy Policy
  • |
  • Contact Us